title: Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.
abstract: BACKGROUND
  Based on the results of phase I/II studies, S-1 plus cisplatin (CDDP) and vinorelbine (VNR) plus CDDP are commonly used chemoradiotherapeutic regimens for the treatment of non-small cell lung cancer(NSCCLC) in Japan. However, there have been no studies that have compared S-1 and CDDP combined with thoracic radiotherapy (TRT) with VNR and CDDP combined with TRT.
  
  
  METHODS
  A total of 39 and 50 patients with stage III non-small cell lung cancer (NSCLC) were treated with S-1 and CDDP plus concurrent TRT, or with VNR and CDDP plus concurrent TRT, respectively, between 2002 and 2010.
  
  
  RESULTS
  In the S-1 plus CDDP plus TRT group, the median progression-free survival (PFS) and the median overall survival (OS) were 327 days and 1012 days, respectively. In the VNR plus CDDP plus TRT group, the median PFS and the median OS were 328 days and 905 days, respectively. The differences in the PFS and OS were not statistically significant. Grade 3 or more leukopenia and neutropenia were significantly more common in the VNR plus CDDP plus TRT group. Grade 3 or more thrombocytopenia, esophagitis and eruption tended to be more common in the S-1 plus CDDP plus TRT group.
  
  
  CONCLUSIONS
  Due to the difference in the toxicity profiles of the two combinations, S-1 plus CDDP plus TRT or VNR plus CDDP plus TRT should be selected depending on each patient's baseline characteristics.
authors.affiliation: Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-chou, Suntou-gun, Shizuoka, 411-8777, Japan. tshukuya@juntendo.ac.jp
authors.forename: Takehito
authors.initials: T
authors.lastname: Shukuya
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Takahashi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Harada
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Akamatsu
authors.forename: Chikara
authors.initials: C
authors.lastname: Sakaguchi
authors.forename: Hisao
authors.initials: H
authors.lastname: Imai
authors.forename: Akira
authors.initials: A
authors.lastname: Ono
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Asuka
authors.initials: A
authors.lastname: Tsuya
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Kenmotsu
authors.forename: Tateaki
authors.initials: T
authors.lastname: Naito
authors.forename: Haruyasu
authors.initials: H
authors.lastname: Murakami
authors.forename: Masahiro
authors.initials: M
authors.lastname: Endo
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Takahashi
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D014747:Vinblastine; D010094:Oxonic Acid; D002945:Cisplatin; D000077235:Vinorelbine